Mirum Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Mirum Pharmaceuticals has a total shareholder equity of $234.6M and total debt of $306.8M, which brings its debt-to-equity ratio to 130.8%. Its total assets and total liabilities are $652.0M and $417.4M respectively.
Key information
130.8%
Debt to equity ratio
US$306.84m
Debt
Interest coverage ratio | n/a |
Cash | US$302.84m |
Equity | US$234.60m |
Total liabilities | US$417.36m |
Total assets | US$651.96m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MIRM *'s short term assets ($389.5M) exceed its short term liabilities ($105.9M).
Long Term Liabilities: MIRM *'s short term assets ($389.5M) exceed its long term liabilities ($311.5M).
Debt to Equity History and Analysis
Debt Level: MIRM *'s net debt to equity ratio (1.7%) is considered satisfactory.
Reducing Debt: MIRM *'s debt to equity ratio has increased from 0.6% to 130.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MIRM * has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MIRM * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.